{"count": 8, "results": [{"_id": "32241082", "pmid": 32241082, "pmcid": "PMC8009173", "title": "Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells", "journal": "Korean J Intern Med", "authors": ["Na YJ", "Yu ES", "Kim DS", "Lee DH", "Oh SC", "Choi CW"], "date": "2021-03-01T00:00:00Z", "doi": "10.3904/kjim.2019.336", "meta_date_publication": "2021 Mar", "meta_volume": "36", "meta_issue": "Suppl 1", "meta_pages": "S196-S206", "score": 50292.492, "text_hl": "However, the effects of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on @<m>DISEASE_Leukemia_Myelogenous_Chronic_BCR_ABL_Positive</m> @DISEASE_MESH:D015464 @@@CML@@@ have not been elucidated.", "citations": {"NLM": "Na YJ, Yu ES, Kim DS, Lee DH, Oh SC, Choi CW. Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells Korean J Intern Med. 2021 Mar;36(Suppl 1):S196-S206. PMID: 32241082", "BibTeX": "@article{32241082, title={Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells}, author={Na YJ and Yu ES and Kim DS and Lee DH and Oh SC and Choi CW}, journal={Korean J Intern Med}, volume={36}, number={Suppl 1}, pages={S196-S206}}"}}, {"_id": "35132891", "pmid": 35132891, "pmcid": "PMC9047107", "title": "Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia", "journal": "J Oncol Pharm Pract", "authors": ["Pokorny R", "Stenehjem DD", "Gilreath JA"], "date": "2022-06-01T00:00:00Z", "doi": "10.1177/10781552221077254", "meta_date_publication": "2022 Jun", "meta_volume": "28", "meta_issue": "4", "meta_pages": "916-923", "score": 50264.973, "text_hl": "Impact of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on @GENE_TXK @GENE_7294 @@@tyrosine kinase@@@ inhibitor response in @<m>DISEASE_Leukemia_Myelogenous_Chronic_BCR_ABL_Positive</m> @DISEASE_MESH:D015464 @@@chronic myeloid leukemia@@@", "citations": {"NLM": "Pokorny R, Stenehjem DD, Gilreath JA. Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia J Oncol Pharm Pract. 2022 Jun;28(4):916-923. PMID: 35132891", "BibTeX": "@article{35132891, title={Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia}, author={Pokorny R and Stenehjem DD and Gilreath JA}, journal={J Oncol Pharm Pract}, volume={28}, number={4}, pages={916-923}}"}}, {"_id": "37903788", "pmid": 37903788, "pmcid": "PMC10616083", "title": "AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous leukemia (CML) subjects", "journal": "Cell Death Discov", "authors": ["Gayatri MB", "Kancha RK", "Behera A", "Patchva D", "Velugonda N", "Gundeti S", "Reddy ABM"], "date": "2023-10-30T00:00:00Z", "doi": "10.1038/s41420-023-01700-x", "meta_date_publication": "2023 Oct 30", "meta_volume": "9", "meta_issue": "1", "meta_pages": "401", "score": 50260.297, "text_hl": "Since @GENE_CD34 @GENE_947 @@@CD34@@@ considered as @<m>DISEASE_Leukemia_Myelogenous_Chronic_BCR_ABL_Positive</m> @DISEASE_MESH:D015464 @@@CML@@@ initiating cells, we then analyzed the expression levels by western blot, the results showed that the expression of @GENE_CD34 @GENE_947 @@@CD34@@@ levels were significantly reduced upon @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ treatment which demonstrates that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ has potential to kill even @<m>DISEASE_Leukemia_Myelogenous_Chronic_BCR_ABL_Positive</m> @DISEASE_MESH:D015464 @@@CML@@@ initiating cells (Fig. 6F).", "citations": {"NLM": "Gayatri MB, Kancha RK, Behera A, Patchva D, Velugonda N, Gundeti S, Reddy ABM. AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous leukemia (CML) subjects Cell Death Discov. 2023 Oct 30;9(1):401. PMID: 37903788", "BibTeX": "@article{37903788, title={AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous leukemia (CML) subjects}, author={Gayatri MB and Kancha RK and Behera A and Patchva D and Velugonda N and Gundeti S and Reddy ABM}, journal={Cell Death Discov}, volume={9}, number={1}, pages={401}}"}}, {"_id": "35444236", "pmid": 35444236, "pmcid": "PMC9021200", "title": "Mitochondrial oxidative phosphorylation is dispensable for survival of CD34+ chronic myeloid leukemia stem and progenitor cells", "journal": "Cell Death Dis", "authors": ["Yan JS", "Yang MY", "Zhang XH", "Luo CH", "Du CK", "Jiang Y", "Dong XJ", "Wang ZM", "Yang LX", "Li YD", "Xia L", "Lu Y"], "date": "2022-04-20T00:00:00Z", "doi": "10.1038/s41419-022-04842-5", "meta_date_publication": "2022 Apr 20", "meta_volume": "13", "meta_issue": "4", "meta_pages": "384", "score": 50258.203, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ kills @<m>DISEASE_Leukemia_Myelogenous_Chronic_BCR_ABL_Positive</m> @DISEASE_MESH:D015464 @@@CML@@@ @GENE_CD34 @GENE_947 @@@CD34@@@+ cells", "citations": {"NLM": "Yan JS, Yang MY, Zhang XH, Luo CH, Du CK, Jiang Y, Dong XJ, Wang ZM, Yang LX, Li YD, Xia L, Lu Y. Mitochondrial oxidative phosphorylation is dispensable for survival of CD34+ chronic myeloid leukemia stem and progenitor cells Cell Death Dis. 2022 Apr 20;13(4):384. PMID: 35444236", "BibTeX": "@article{35444236, title={Mitochondrial oxidative phosphorylation is dispensable for survival of CD34+ chronic myeloid leukemia stem and progenitor cells}, author={Yan JS and Yang MY and Zhang XH and Luo CH and Du CK and Jiang Y and Dong XJ and Wang ZM and Yang LX and Li YD and Xia L and Lu Y}, journal={Cell Death Dis}, volume={13}, number={4}, pages={384}}"}}, {"_id": "37171230", "pmid": 37171230, "title": "Metformin exerts antileukemic effects by modulating lactate metabolism and overcomes imatinib resistance in chronic myelogenous leukemia.", "journal": "FEBS J", "authors": ["Gayatri MB", "Kancha RK", "Patchva D", "Velugonda N", "Gundeti S", "Reddy ABM"], "date": "2023-05-12T00:00:00Z", "doi": "10.1111/febs.16818", "meta_date_publication": "2023 May 12", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50255.184, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ exerts antileukemic effects by modulating @CHEMICAL_Lactic_Acid @CHEMICAL_MESH:D019344 @@@lactate@@@ metabolism and overcomes @CHEMICAL_Imatinib_Mesylate @CHEMICAL_MESH:D000068877 @@@imatinib@@@ resistance in @<m>DISEASE_Leukemia_Myelogenous_Chronic_BCR_ABL_Positive</m> @DISEASE_MESH:D015464 @@@chronic myelogenous leukemia@@@.", "citations": {"NLM": "Gayatri MB, Kancha RK, Patchva D, Velugonda N, Gundeti S, Reddy ABM. Metformin exerts antileukemic effects by modulating lactate metabolism and overcomes imatinib resistance in chronic myelogenous leukemia. FEBS J. 2023 May 12;():. PMID: 37171230", "BibTeX": "@article{37171230, title={Metformin exerts antileukemic effects by modulating lactate metabolism and overcomes imatinib resistance in chronic myelogenous leukemia.}, author={Gayatri MB and Kancha RK and Patchva D and Velugonda N and Gundeti S and Reddy ABM}, journal={FEBS J}}"}}, {"_id": "32769032", "pmid": 32769032, "title": "Action of metformin therapy against advanced glycation, oxidative stress and inflammation in type 2 diabetes patients: 3 months follow-up study.", "journal": "Diabetes Metab Syndr", "authors": ["Adeshara KA", "Bangar NS", "Doshi PR", "Diwan A", "Tupe RS"], "date": "2020-09-01T00:00:00Z", "doi": "10.1016/j.dsx.2020.07.036", "meta_date_publication": "2020 Sep-Oct", "meta_volume": "14", "meta_issue": "5", "meta_pages": "1449-1458", "score": 50239.797, "text_hl": "Action of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ therapy against advanced glycation, oxidative stress and @DISEASE_Inflammation @DISEASE_MESH:D007249 @@@inflammation@@@ in @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes@@@ @SPECIES_9606 @@@patients@@@: 3 months follow-up study.", "citations": {"NLM": "Adeshara KA, Bangar NS, Doshi PR, Diwan A, Tupe RS. Action of metformin therapy against advanced glycation, oxidative stress and inflammation in type 2 diabetes patients: 3 months follow-up study. Diabetes Metab Syndr. 2020 Sep-Oct;14(5):1449-1458. PMID: 32769032", "BibTeX": "@article{32769032, title={Action of metformin therapy against advanced glycation, oxidative stress and inflammation in type 2 diabetes patients: 3 months follow-up study.}, author={Adeshara KA and Bangar NS and Doshi PR and Diwan A and Tupe RS}, journal={Diabetes Metab Syndr}, volume={14}, number={5}, pages={1449-1458}}"}}, {"_id": "22249159", "pmid": 22249159, "pmcid": "PMC3282089", "title": "AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications", "journal": "Oncotarget", "authors": ["Vakana E", "Platanias LC"], "date": "2011-12-01T00:00:00Z", "doi": "10.18632/oncotarget.413", "meta_date_publication": "2011 Dec", "meta_volume": "2", "meta_issue": "12", "meta_pages": "1322-8", "score": 50065.316, "text_hl": "The potential for future clinical-translational applications of @GENE_PRKAA2 @GENE_5563 @@@AMPK@@@ activators such as AICAR, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and @CHEMICAL_Resveratrol @CHEMICAL_MESH:D000077185 @@@resveratrol@@@ for the treatment of @<m>DISEASE_Leukemia_Myelogenous_Chronic_BCR_ABL_Positive</m> @DISEASE_MESH:D015464 @@@chronic myelogenous leukemia@@@ (@<m>DISEASE_Leukemia_Myelogenous_Chronic_BCR_ABL_Positive</m> @DISEASE_MESH:D015464 @@@CML@@@) and @DISEASE_Precursor_Cell_Lymphoblastic_Leukemia_Lymphoma @DISEASE_MESH:D054198 @@@Ph+ acute lymphoblastic leukemia@@@ (@DISEASE_Precursor_Cell_Lymphoblastic_Leukemia_Lymphoma @DISEASE_MESH:D054198 @@@ALL@@@) are discussed.", "citations": {"NLM": "Vakana E, Platanias LC. AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications Oncotarget. 2011 Dec;2(12):1322-8. PMID: 22249159", "BibTeX": "@article{22249159, title={AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications}, author={Vakana E and Platanias LC}, journal={Oncotarget}, volume={2}, number={12}, pages={1322-8}}"}}, {"_id": "26186064", "pmid": 26186064, "title": "The antileukemia effect of metformin in the Philadelphia chromosome-positive leukemia cell line and patient primary leukemia cell.", "journal": "Anticancer Drugs", "authors": ["Shi R", "Lin J", "Gong Y", "Yan T", "Shi F", "Yang X", "Liu X", "Naren D"], "date": "2015-10-01T00:00:00Z", "doi": "10.1097/CAD.0000000000000266", "meta_date_publication": "2015 Oct", "meta_volume": "26", "meta_issue": "9", "meta_pages": "913-22", "score": 50056.688, "text_hl": "Overall, our data suggest that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ represents a promising and attractive agent for @DISEASE_Precursor_Cell_Lymphoblastic_Leukemia_Lymphoma @DISEASE_MESH:D054198 @@@Ph+ALL@@@ or @<m>DISEASE_Leukemia_Myelogenous_Chronic_BCR_ABL_Positive</m> @DISEASE_MESH:D015464 @@@CML@@@ therapy. ", "citations": {"NLM": "Shi R, Lin J, Gong Y, Yan T, Shi F, Yang X, Liu X, Naren D. The antileukemia effect of metformin in the Philadelphia chromosome-positive leukemia cell line and patient primary leukemia cell. Anticancer Drugs. 2015 Oct;26(9):913-22. PMID: 26186064", "BibTeX": "@article{26186064, title={The antileukemia effect of metformin in the Philadelphia chromosome-positive leukemia cell line and patient primary leukemia cell.}, author={Shi R and Lin J and Gong Y and Yan T and Shi F and Yang X and Liu X and Naren D}, journal={Anticancer Drugs}, volume={26}, number={9}, pages={913-22}}"}}]}